{"id":"NCT02016482","sponsor":"AbbVie","briefTitle":"A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis","officialTitle":"A Phase 3, Multicenter, Double-Blind, Randomized, Parallel-Arm, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Adalimumab for Treatment of Nail Psoriasis in Patients With Chronic Plaque Psoriasis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-01","primaryCompletion":"2015-10","completion":"2016-04","firstPosted":"2013-12-20","resultsPosted":"2017-02-13","lastUpdate":"2017-05-30"},"enrollment":217,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Nail Psoriasis","Plaque Psoriasis"],"interventions":[{"type":"BIOLOGICAL","name":"Adalimumab","otherNames":["ABT-D2E7","Humira"]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Adalimumab (ADA)","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"This study is being conducted to assess the safety and efficacy of adalimumab in participants with nail psoriasis.","primaryOutcome":{"measure":"Percentage of Participants Achieving a Total Fingernail Modified Nail Psoriasis Severity Index (mNAPSI) 75 Response at Week 26","timeFrame":"Week 26","effectByArm":[{"arm":"Placebo","deltaMin":3.4,"sd":null},{"arm":"Adalimumab EOW","deltaMin":46.6,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"< 0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":108},"commonTop":["NASOPHARYNGITIS","UPPER RESPIRATORY TRACT INFECTION","PSORIASIS","GASTROENTERITIS","ARTHRALGIA"]}}